Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: a case-crossover analysis. Clin Endocrinol (Oxf). 2018 May;88(5):719-27. doi: 10.1111/cen.13574
Alvarez-Pedrerol M, Ribas-Fito N, Garcia-Esteban R, Rodriguez A, Soriano D, Guxens M, Mendez M, Sunyer J. Iodine sources and iodine levels in pregnant women from an area without known iodine deficiency. Clin Endocrinol (Oxf). 2010 Jan;72(1):81-6. doi: 10.1111/j.1365-2265.2009.03588.x
Mauskopf J, Paramore C, Lee WC, McBurney CR, Snyder EH. Drug persistence is similar with rivastigmine and donepezil in Alzheimer's disease patients. Neurobiol Aging. 2004 Jan 1;25:S204.
Hauber B, Candrilli S, Snyder EH, McBurney CR. Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine. Neurobiol Aging. 2004 Jan 1;25:S136.
Ofman J, Hauber B, Deal L, Mauskopf J, Snyder E. Costs and benefits of rivastigmine treatment for Alzheimer's disease in the US. Neurobiol Aging. 2002 Jan 1;23(1):476.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.